{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"title":"Experienced aGVHD, later relapsed"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"title":"No aGVHD occurence, relapsed"}],"denoms":[{"counts":[{"groupId":"OG000","value":"67"}],"units":"Participants"}],"description":"An event is defined as relapse; estimated probability of relapse.","groups":[{"description":"Relative contribution of ALL blasts to the donor immune response as a cause of relapse post transplantation (correlating development of aGVHD with relapse).","id":"OG000","title":"All Patients"}],"paramType":"NUMBER","populationDescription":"Number at risk among no aGVHD and number at risk among aGVHD at 1 year. The two treatment regimens were intended to be analyzed together (combined data), as pre-specified in the study protocol, therefore results are not reported for each Arm of study.","reportingStatus":"POSTED","timeFrame":"At 1 year","title":"Relative Contribution of ALL Blasts to the Donor Immune Response as a Cause of Relapse Post Transplantation (Correlating Development of aGVHD With Relapse)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}